{
  "id": 10883833,
  "title": "AbbVIe's Zumilokibart Meets Phase 2 Goal In Atopic Dermatitis Study",
  "url": "https://urgent.news/2026/09/30/abbvies-zumilokibart-meets-phase-2-goal-in-atopic-dermatitis-study",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-30T06:14:10.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/abbvies-zumilokibart-meets-phase-2-goal-atopic-dermatitis-study"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - AbbVie (ABBV) reported positive results from the Phase 2 APEX Part B study of zumilokibart, in adults with moderate to severe atopic dermatitis.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "AbbVie’s zumilokibart meets phase 2 atopic dermatitis endpoint",
        "url": "https://urgent.news/2026/09/30/abbvies-zumilokibart-meets-phase-2-atopic-dermatitis-endpoint",
        "published": "2026-09-30T05:36:31.000Z"
      },
      {
        "outlet": "Seeking Alpha News",
        "title": "AbbVie reports positive phase 2 data for Zumilokibart in atopic dermatitis",
        "url": "https://urgent.news/2026/09/30/abbvie-reports-positive-phase-2-data-for-zumilokibart-in-atopic",
        "published": "2026-09-30T06:25:15.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}